A number of studies have been done to elucidate the possible association between the UGT2B17 null genotype and risks for different types of tumor in diverse populations, such as prostate tumors [15]–[20], lung tumors [10], [21], breast tumors [22], and colorectal tumors [23]. This evidence concerns the gene UGT2B17 and prostate neoplasm.